Palisade Bio Inc. diskutieren
Palisade Bio Inc.
WKN: A3DZ0T / Symbol: PALI / Name: Palisade Bio / Aktie / Pharmazeutika / Small Cap /
0,34 €
-6,68 %
Sell Seneca Biopharma Inc.
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its price target lowered by analysts at Maxim Group from $22.50 to $8.00. They now have a "buy" rating on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $38.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen to a "sell" rating.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Neueste Beiträge
BTIG_Research in PennyMac Financial Services, Inc. diskutieren